Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 1059-1063

  Cetin, Bulent ^a   Kaplan, Mehmet Ali ^b   Berk, Veli ^c   Ozturk, Selcuk Cemil ^b   Benekli, Mustafa ^a   Isikdogan, Abdurrahman ^b   Ozkan, Metin ^c   Coskun, Ugur ^a   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Bevacizumab; Metastatic colorectal cancer; Prognostic factors; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE PLUS OXALIPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX; VASCULOTROPIN;

ARTICLE; BLOOD; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; L-LACTATE DEHYDROGENASE; LEUCOVORIN; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84871915206     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.1059     Document Type: Article

References (24)

1. Burzykowski T, Molenberghs G, Buyse M (2001). Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. J Roy Stat Soc C Appl Stat, 50, 405-22.
2. Buyse M, Burzykowski T, Carroll K, et al (2007). Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol, 25, 5218-24.
3. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al (2008). Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate endpoints in metastatic breast cancer. J Clin Oncol, 26, 1987-92.
4. Coiffier B, Gisselbrecht C, Vose JM, et al (1991). Prognostic factors in aggressive malignant lymphomas. Description and validation of prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol, 9, 211-19.
5. Collette L, Burzykowski T, Carroll KJ, et al (2005). Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? J Clin Oncol, 23, 6139-48.
6. de Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol, 18, 2938-47.
7. Dimopoulos MA, Barlogie B, Smith TL, et al (1991). High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med, 115, 931-35.
8. Donskov F, von der Maase H (2006). Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol, 24, 1997-05.
9. Ferrara N, Hillan KJ, Gerber HP, et al (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, 391.
10. Ferrara N (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 25, 581-?.
11. Grothey A, Hedrick EE, Mass RD, et al (2008). Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol, 26, 183-89.
12. Hecht JR, Trarbach T, Jaeger E (2005). A randomized, double-blind,placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol, 23, 16S (abstr LBA3).
13. Heng DY, Xie W, Regan MM, et al (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents:results from a large, multicenter study. J Clin Oncol, 27, 5794-99.
14. Hollen CW, Henthorn J, Koziol JA, et al (1992). Serum interleukin-6 levels in patients with thrombocytosis. Leuk Lymphoma, 8, 235-41.
15. Kemeny N, Braun DW Jr (1983). Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med, 74, 786-94.
16. Kerbel RS, Kamen BA (2004). The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer, 4, 423-?.
17. Mancuso P, Colleoni M, Calleri A, et al (2006). Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood, 108, 452-?.
18. Nisman B, Barak V, Hubert A, et al (2003). Prognostic factors for survival in metastatic breast cancer during first line paclitaxel chemotherapy. Anticancer Res, 23, 1939-42.
19. Saltz L, Cox JV, Blanke C, et al (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 343, 905-14.
20. Suppiah R, Shaheen PE, Elson P, et al (2006). Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer, 107, 1793-00.
21. Tas F, Aykan F, Alici S, et al (2001). Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol, 24, 547-50.
22. Tas F, Aydiner A, Demir C, et al (2001). Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol, 24, 376-78.
23. Tournigand C, Andre T, Achille E, et al (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 22, 229-37.
24. Tournigand C, Cervantes A, Figer A, et al (2006). OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol, 24, 394-00.